6:10 PM
 | 
Jan 07, 2013
 |  BC Extra  |  Clinical News

Celgene reports psoriasis data, provides 2013 outlook

Celgene Corp. (NASDAQ:CELG) said twice-daily apremilast met the primary endpoint of improving PASI 75 response rate at week 16 vs. placebo in the Phase III ESTEEM 1 and ESTEEM 2 trials to treat moderate to severe plaque psoriasis. Celgene plans to submit an NDA to FDA in 1Q13 for apremilast to treat...

Read the full 244 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >